Roger Deeley, PhD FRSC FCAHS
Dr. Roger Deeley is the President of the Kingston General Hospital Research Institute. He also holds the positions of Vice President, Health Sciences Research at Kingston General Hospital, Vice-Dean Research in the Faculty of Health Sciences at Queen’s University, and an endowed chair in basic oncology. Previously Dr. Deeley served as Vice President and then Director of Research for Cancer Care Ontario. He was also one of the founders and the first Director of the Queen’s University Cancer Research Institute, a position he held for 13 years. Dr. Deeley has extensive experience working with provincial and federal health research funding agencies, charities and the private sector.
Prior to moving to Canada, Dr. Deeley spent 10 years as a scientist at the US National Cancer Institute and since then has maintained a highly successful research career studying mechanisms of resistance to cancer therapeutics. His pioneering work, with Queen’s University co-investigator Dr. Susan Cole, and their subsequent discovery of the gene coding for a multidrug resistance protein (MRP), represented a significant advancement in scientific understanding of how the body deals with drugs, toxins and other chemicals. Author of approximately 200 peer-reviewed publications and book chapters, and with more than 17,000 citations, Dr. Deeley is also a named inventor on 12 patents worldwide relating to this work, which continues to contribute significantly to drug development and cancer research.
In 2005, he was a recipient of the Robert L. Noble Prize presented jointly by the National Cancer Institute of Canada and the Canadian Cancer Society, and in 2007 received a National Cancer Institute of Canada’s Diamond Jubilee Award, both for outstanding contributions to cancer research. In 2013, he became a fellow of the Canadian Academy of Health Sciences, and in 2014 he was elected to the Royal Society of Canada.